220 related articles for article (PubMed ID: 19074536)
1. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
[TBL] [Abstract][Full Text] [Related]
2. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
[TBL] [Abstract][Full Text] [Related]
3. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
[TBL] [Abstract][Full Text] [Related]
4. The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment.
Harvey PD; Endicott JM; Loebel AD
Bipolar Disord; 2008 Dec; 10(8):900-6. PubMed ID: 19594505
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies.
Stahl S; Lombardo I; Loebel A; Mandel FS
J Affect Disord; 2010 Apr; 122(1-2):39-45. PubMed ID: 19616304
[TBL] [Abstract][Full Text] [Related]
6. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
[TBL] [Abstract][Full Text] [Related]
7. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
Smulevich AB; Khanna S; Eerdekens M; Karcher K; Kramer M; Grossman F
Eur Neuropsychopharmacol; 2005 Jan; 15(1):75-84. PubMed ID: 15572276
[TBL] [Abstract][Full Text] [Related]
8. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial.
Akhondzadeh S; Milajerdi MR; Amini H; Tehrani-Doost M
Bipolar Disord; 2006 Oct; 8(5 Pt 1):485-9. PubMed ID: 17042886
[TBL] [Abstract][Full Text] [Related]
9. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
[TBL] [Abstract][Full Text] [Related]
10. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
[TBL] [Abstract][Full Text] [Related]
11. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
McIntyre RS; Konarski JZ; Jones M; Paulsson B
J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
[TBL] [Abstract][Full Text] [Related]
13. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial.
McIntyre RS; Brecher M; Paulsson B; Huizar K; Mullen J
Eur Neuropsychopharmacol; 2005 Oct; 15(5):573-85. PubMed ID: 16139175
[TBL] [Abstract][Full Text] [Related]
15. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania.
Ketter TA; Jones M; Paulsson B
J Affect Disord; 2007; 100 Suppl 1():S45-53. PubMed ID: 17383011
[TBL] [Abstract][Full Text] [Related]
16. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
[TBL] [Abstract][Full Text] [Related]
17. Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study.
Vieta E; Pappadopulos E; Mandel FS; Lombardo I
Int J Neuropsychopharmacol; 2011 Sep; 14(8):1017-27. PubMed ID: 21396153
[TBL] [Abstract][Full Text] [Related]
18. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
19. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
Citrome L
Expert Rev Neurother; 2010 Jul; 10(7):1031-7. PubMed ID: 20586686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
